ABSTRACT
Background Respiratory Syncytial Virus (RSV) is the most common cause of bronchiolitis and lower respiratory tract infections in children in their first year of life, disproportionately affecting infants in developing countries. Previous studies have found that the nasopharyngeal microbiome of infants with RSV infection has specific characteristics that correlate with disease severity, including lower biodiversity, perturbations of the microbiota and differences in relative abundance. These studies have focused on infants seen in clinical or hospital settings, predominantly in developed countries.
Methods We conducted a nested case control study within a random sample of 50 deceased RSV+ infants with age at death ranging from 4 days to 6 months and 50 matched deceased RSV-infants who were all previously enrolled in the Zambia Pertussis and RSV Infant Mortality Estimation (ZPRIME) study. All infants died within the community or within 48 hours of facility admittance. As part of the ZPRIME study procedures, all decedents underwent one-time, post-mortem nasopharyngeal sampling. The current analysis explored the differences between the nasopharyngeal microbiome profiles of RSV+ and RSV-decedents using 16S ribosomal DNA sequencing.
Results We found that Moraxella was more abundant in the nasopharyngeal microbiome of RSV+ decedents than in RSV-decedents. Additionally, Gemella and Staphylococcus were less abundant in RSV+ decedents than in RSV-decedents.
Conclusion These results support previously reported findings of the association between the nasopharyngeal microbiome and RSV and suggest that changes in the abundance of these microbes are likely specific to RSV and may correlate with mortality associated with the disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work was supported by the Bill and Melinda Gates Foundation; W.E.J and J.M. were funded in part by NIH grant R01 GM127430; W.E.J. and A.R.O.M were supported in part by the NIH under grant R21 AI154387
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Boston University Medical Center and the University of Zambia gave ethical approval for the ZPRIME study, where our data originates.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw data is available on the sequence read archive, accession number PRJNA913857. All processed data and code used for data preprocessing, statistical analysis, and figure generation is available on GitHub (https://github.com/jessmcc22/ZPRIME_RSV).
